Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany.
| FactSnippet No. 1,007,177 |
15 Facts About Evotec
2.
Evotec operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.
| FactSnippet No. 1,007,178 |
3.
On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing.
| FactSnippet No. 1,007,179 |
4.
On 8 November 2021, Evotec completed its secondary listing on the U S Nasdaq stock exchange on November 8 and raised $500 million.
| FactSnippet No. 1,007,180 |
5.
Evotec SE was established as Evotec BioSystems GmbH in 1993 by a group of founders that included Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Schulte, Rudolf Rigler, Charles Weissmann and Nobel Laureate Manfred Eigen.
| FactSnippet No. 1,007,181 |
6.
Evotec Biosystems went public in 1999, listing on the Frankfurt Stock Exchange under the ticker symbol EVT.
| FactSnippet No. 1,007,182 |
7.
Four years later, this division was sold to PerkinElmer in a move that, according to Evotec, allowed it to focus its resources towards the discovery and development of new pharmaceutical drugs.
| FactSnippet No. 1,007,183 |
8.
In 2011, Evotec acquired Kinaxo Biotechnologies GmbH, a Munich-based, privately owned biotech company.
| FactSnippet No. 1,007,184 |
9.
That same year, Evotec took control of Compound Focus the compound management arm of the Galapagos group subsidiary Biofocus.
| FactSnippet No. 1,007,185 |
10.
In January 2013, Evotec acquired CCS Cell Culture Service GmbH, a Hamburg-based company that supplied custom cells and cell-based reagents for drug discovery applications.
| FactSnippet No. 1,007,186 |
11.
In December 2016, Evotec completed its acquisition of Cyprotex, a preclinical contract research organization.
| FactSnippet No. 1,007,187 |
12.
In recent years, Evotec has made two significant deals with French pharmaceutical company Sanofi.
| FactSnippet No. 1,007,188 |
14.
Evotec's initial focus will be on antimicrobial resistance and superbug infections, tuberculosis, and malaria, as well as the creation of novel antiviral therapies with new mechanisms of action.
| FactSnippet No. 1,007,190 |
15.
In May 2022, Evotec announced the company are set to acquire Italy-based cell technology firm Rigenerand.
| FactSnippet No. 1,007,191 |